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Abstract 
The use of umbilical stem cells in tissue engineering is gaining in popularity. Some of the various 
uses of these umbilical stem cells are highlighted in this review, focusing mainly on their cartilage, 
bone and neuronal differentiating abilities. The review will also shed light on the application of 
these abilities in human clinical trials to repair, protect and treat diseases, e.g. neurodegenerative 
diseases such as Alzheimer’s and cerebral palsy. A side by side comparison with bone marrow 
mesenchymal stem cells (current gold standard for tissue engineering) will give a better idea of 
the viability and efficiency of umbilical stem cell use. 
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1. Introduction 
1.1. Anatomy of Umbilical Cord 
The human umbilical cord (UC) in itself contains distinct anatomical regions consisting of an umbilical vein, 
two umbilical arteries, cord lining, and Wharton’s jelly (this jelly-like tissue surrounds the blood vessels and 
plays the functional role in supporting the vessels) [1]. 
1.2. Uses of Umbilical Stem Cells 
Throughout recent history the literature has described each of these regions as giving rise to a great number of 
fibroblastoid mesenchymal stem cells (MSCs). Refer to Figure 1 for a simple illustration of cord anatomy and 
differentiating abilities of umbilical stem cells. Human umbilical cord derived MSCs (HUCMSCs) isolated from 
the cord’s structures; arteries, vein, cord lining and Wharton’s jelly have all been shown to be multipotent in na-
ture, differentiating into many cell types such as adipocytes [1], osteoblasts [2], hepatocytes [3], chondrocytes  
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Figure 1. Diagrammatic representation of cord cross-section and differentiation schematic diagram of HUCMSCs. This 
figure provides a simple diagrammatic representation of the umbilical cord with its two arteries and vein separated by an 
intervascular area which is immediately surrounded by a perivascular area and subamniotic later after that. As listed above 
these mesenchymal stromal cells are capable in differentiating into many different cells types and tissues. These stem cells’ 
vast differentiating ability coupled with their natural abundance leads to them being a very reasonable and efficient source 
for tissue engineering [2].                                                                                     
 
[2], haemopoetic cells [4], cardiac [5] and neural cells [6] [7]. Umbilical cord stem cells have also been proved 
promising in possible treatment of several diseases and conditions such as diabetes [8], certain diabetic wounds 
[9], and brain damage associated with neonatal hypoxia [10], stroke [11], autism [12], acute liver failure [13], 
cerebral palsy [6] [14] and Alzheimer’s [15]. They have also been found to express markers typically expressed 
by bone marrow derived MSCs (BMSCs), whilst testing negative for markers of haematopoietic and macro-
phage nature [1].  
1.3. Umbilical Stem Cells VS Bone Marrow Stem Cells 
For a long time bone marrow has been considered as the “crème de la crème” when it comes to the derivation of 
MSCs and their use in human stem cell engineering has become somewhat of a standard. However, bone mar-
row extraction comes with ethical issues and various problems related to painful harvesting and donor site injury 
and morbidity. However, UCs are being looked into as a potential source of MSCs for various advantageous 
reasons; not only do they proliferate rapidly in culture and are thought to be immune privileged against certain 
antigens but they are considered as waste within medical community and therefore their potential use in research 
has little ethical concern unlike bone marrow harvesting [1].  
BMSCs in comparison with HUCMSCs have shown notable changes with increasing patient age, such as 
lower differentiation potential in vitro, reduction in available cell number and also longer doubling times. As 
mentioned, HUCMSCs are thought to have an immune privileged status not unlike BMSC and an immuno-
modulatory phenotype resourceful in moderating and suppressing the immune response in vitro and therefore 
also make them a worthy candidate for allogeneic cell based therapies. Thus UC MSCs are proving to be an ap-
propriate source of primitive MSCs that can be cryogenically stored in banks and thawed when their therapeutic 
abilities are needed [1].  
1.4. This Review 
This review will serve to identify some of the various uses of human umbilical cord stem cells. Throughout the 
review the advantages as well as shortcomings of this MSC type will be highlighted, also giving an insight into 
the future of HUCMSCs. 
2. Cartilage: HUCMSCs Promising Finds in Fibrocartilage Engineering. Possibilities 
for Hyaline Cartilage in the Future 
2.1. Growth Factors and Chondrocyte Differentiation 
Damaged cartilage has minimal self-regeneration abilities. Compared with the present day treatments such as ar-
tificial prosthesis, cell-based implantation and microfracture, stem cells have the potential of becoming the go to 
treatment in terms of cartilage function restoration. Due to the self-generating and differentiating abilities of 
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mesenchymal stem cells such as HUMSCs, stem cells have become a viable source for cartilage engineering. 
Tissue growth factor (TGF) isoforms (TGF-β1, β2 and β3) have been found to trigger the differentiation of 
MSCs into chondrocytes while dexamethasone has been found to improve and enhance differentiation [2]. Insu-
lin-like growth factor-1 (IGF-1) and its role in chondrogenic differentiation still remains somewhat controversial. 
After the removing insulin from the insulin-transferrin-selenious acid Premix (1X serum substitute Premix), a 
serum-free chondrogenic foetal bovine serum artificial medium, IGF-I showed equal chondroinductive capabil-
ity with MSCs when compared with TGF-β isoforms. Experimentation also showed that a chondrogenic ana-
bolic medium with IGF-1, previously containing TGF-B instead of IGF-1, increased noticeably the synthesis 
and gene expression of collagen type II apart from increasing collagen production in relation to chondrogenic 
medium [16]. 
TGF-βs, as with other mesenchymal stem cells, are able to influence HUCMSCs and direct them towards a 
chondrogenic lineage. They are grown in 3D cell pellets and specially designed polyglycolic acid (PGA) scaf-
folds (this biodegradable polyester, PGA, is being exploited in a variety of medical applications). However in 
more recent years a new method of HUCMSC chondrocyte differentiation was developed involving the upregu-
lation of SOX-9, a main regulatory gene in chondrogenesis and the initiation of the chondrogenic differentiation 
of HUCMSCs at the level of mRNA [17]. 
2.2. Inconsistent Results 
Confirmation of chondrogenic differentiation in terms of extracellular proteins was verified by immunohisto-
chemal staining and antigen retrieval for type II collagen and also by Alcian blue staining for glycosaminogly-
cans (GAGs) [2]. However studies have yielded inconsistent results regarding HUCMSCs chondrogenic differ-
entiation. 
 In the control group (not containing TGF β1) of an experiment conducted by [18], there was a noted positive 
staining for both collagen type II and GAGs. However, in an experiment of a similar nature, there was no type II 
collagen production noted within the control group, although in HBMSCs only a slight amount of type II colla-
gen was detected [19], contrasting significantly with previous HBMSC studies where the formation of collagen 
type had been abundant [2]. 
2.3. HUCMSCs Outcompeting HBMSCs and Possible Applications 
In this study both HBMSCs and HUCMSCs contributed to the formation of collagen type 1. However the 
HUCMSC group produced larger pellets, with a filamentous extracellular matrix bettering that produced by 
HBMSCs. Furthermore, the glycosaminoglycan (GAG) quantification showed that a subpopulation of the 
HUCMSCs, known as the perivascular cells, produced an amount of GAGs similar to that produced by 
HBMSCs after just 21 days, admittingly the first week saw the perivascular cells producing less GAGs than then 
the HBMSC groups. Comparing HBMSCs with HUCMSCs the latter has better differentiating ability, can gen-
erate both type I and II collagen (as found in both biomaterial-based and cell pellet culture). HUCMSCs also 
outcompeted HBMSCs with better extracellular matrix synthesis and increased production of collagen and 
GAGs. However HBMSCs was found to advance more along the chondrogenic lineages with increased protein 
levels and increased levels of collagen type II gene expression. This study continued to secure HUCMSCs’ place 
in fibrocartilage tissue engineering, being an appropriate substitute for the development of fibrocartilagenous 
tissues. Possible applications include the treatment of damaged intervertebral discs, temporomandibular joint 
(TMJ) discs, and knee menisci [2]. 
2.4. HUCMSCs Outperform TMJ Condylar Cartilage Cells 
The very first in depth study into in vitro utilization of HUCMSCs cartilage differentiating abilities, compared 
the TMJ regeneration between the stem cells and TMJ condylar cartilage cells. After both types of cells were 
subjected to a 4-week long culture in PGA scaffolds, not only did the HUCMSCs match the native TMJ carti-
lage in terms of the similar fibrocartilage-like tissue produced but actually performed better than the TMJ 
condylar cartilage cells, with an increase of both collagen and GAGs as well as cellularity. Due to the limited 
supply of TMJ cells compared to the more abundant HUCMSCs, these MSCs were suggested as an ideal source 
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for TMJ condylar cartilage regeneration [2]. 
2.5. Optimum Seeding Cell Density 
After having established that HUCMSCs indeed were viable for fibrocartilage tissue engineering, further studies 
were undertaken in order to discover what were the effects of cell seeding densities on different criteria such as 
matrix synthesis, cell proliferation and their differentiation. After experimenting with different cell densities, a 
seeding density higher than that of 25 million cells/ml was advised for future studies in fibrocartilage tissue en-
gineering. The HUCMSCs differentiated along a fibrocartilage lineage with excellent results, producing a very 
viable fibrocartilage-like tissue with the necessary co-existing components of aggrecan, collagen type I and II. 
These studies proved HUCMSCs, yet again, to be an ideal cell alternative for fibrocartilage regeneration [20]. 
2.6. Future of HUCMSCs in Hyaline Cartilage Engineering 
The use of HUCMSCs in the engineering of hyaline cartilage is still an undergoing study. Some of the main is-
sues lie in the need for further investigation into the required signals that will further enhance and boost type II 
collagen production necessary for hyaline cartilage engineering [21]. Recent studies have hinted towards the 
possible use of hypertrophy markers in studies to come, in order to characterize the phenotype of the developed 
chondrocytes more accurately. Also inhibiting terminal differentiation may not always lead to stable hyaline 
cartilage, as the correct balance of signals must be created from the very start of culture onwards [22]. However 
hyaline engineering using HUCMSCs is still quite young. Maybe exploring the influence of factors such as co-
culture, chemical signals such as aggrecan and growth factors, mechanical stimulation and oxygen tension will 
prove helpful to better chondrogenesis and to one day apply HUCMSCs not only to fibrocartilage but also hya-
line cartilage tissue engineering [2]. 
2.7. Clinical Trials 
Although there has been an increasing number of groups around the world (especially US) that are studying the 
use of HUCMSCs in cartilage repair, the clinical trials to date regarding the use of umbilical stem cells in carti-
lage repair have been few [23], however an ongoing clinical trial is evaluating the use of a newly developed 
treatment CARTISTEM® [23]. A combination of sodium hyaluronate and HUMSCs, this therapeutic agent is 
intended for single-dose use, aimed at cartilage regeneration in humans and restoration of cartilage defects espe-
cially concerning the knee as a result of degenerative diseases, trauma and aging [24]. 
3. Bone: Osteogenic Differentiation and Possible Treatment of Osteoporosis in 
Future 
3.1. Current Bone Treatment and Mesenchymal Stem Cells 
Bone, contrary to cartilage, has a very good blood supply with an intrinsic self-repair and restoring ability. Cur-
rent methods for bone repair and treatment revolve around autologous bone grafts, using the patient’s own bone. 
However this method is associated with certain problems including, infection, malformation and varying degrees 
of donor site morbidity. Decent treatment for certain grave bone injuries are yet to be developed. Being able to 
be integrated directly into biomaterials with optional in vitro cultivation before implantation with minimal side 
effects, bone differentiating mesenchymal stem cells have proved ideal for bone regeneration [25]. 
3.2. Bone Differentiating Abilities of HUCMSCs 
Osteogenic differentiation of HUCMSCs has been triggered by treatment mainly with β-glycerophosphate and 
dexamethasone [18]. Along the duration of osteogenic differentiation the activation of several key player genes 
were noted. The activation of both Runx2, a main regulatory gene of osteogenesis, and TAZ, its transcriptional 
co-activator for osteocalcin expression, were noted [17]. Several studies showed the up-regulation of both os-
teopontin and osteocalcin genes [17] [18]. Throughout the differentiation, positive alkaline phosphatase (ALP), 
a phosphatase usually expressed in high quantities in bone, activity was also noted in certain studies. The forma-
tion of certain bone-specific immunostaining proteins such as osteocalcin, bone sialoprotein-2 and osteonectin 
were prominent. Alizarin red staining and Kossa staining led to the confirmation of mineralisation [2].  
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3.3. BMSCs Compared to HUCMSCs in Bone Differentiation and Formation 
Similarly to HBMSCs, after 2 weeks, mineralisation was observed and the quality of gene expression shown by 
these two MSCs was similar in nature along this time period. However, unlike in chondrogenic studies, 
HBMSCs were shown to outcompete most HUCMSCs in bone formation under certain conditions. Von Kossa 
and alizarin staining revealed that HUCMSCs induced less mineralization when it came to larger bone nodules 
compared to HBMSCs [2]. Even after exposure to dihydroxyvitamin (D3) for the duration of 6 weeks, little os-
teogenesis was shown by the HUCMSCs, with minimal mineralisation and few ALP-positive cells [26].  
Contrary to other inducing agents, HUCMSCs and BMSCs had similar expression of osteogenic phenotypes 
when differentiation was induced by bone morphogenic protein-2, BMP-2, also similar transduction pathways 
were activated in both. HUCMSCs were demonstrated to undergo osteogenic differentiation and proliferation 
when cultured on a calcium phosphate cement. Umbilical stem cells’osteogenic proliferation was inhibited, 
when cultured with a demineralized bone matrix medium, upon examination the stem cells looked flattened and 
shortened, while ALP activity increased substantially [2]. 
Although long lasting cultures will be needed in future to prove the residence of late stage osteogenic markers, 
the research mentioned above confirms that HUCMSCs may progress along the oestogenic lineage. 
3.4. Monolayer Cultures in 3D Biomaterials 
After exposure to osteoinductive biomaterials and chemical signals, monolayer cultures of HUCMSCs, showed 
signs of osteogenic differentiation with the evidence of mineralization and upregulation of osteonectin and 
Runx2 when cultured in 3D biomaterials. In polycaprolactone-tricalcium-phosphate scaffolds HBMSCs were 
found to demonstrate increased osteogenic activity with a significantly larger mineral percentage production 
when compared to that produced by HUCMSCs [2] [27]. 
Through various studies, HUCMSCs have been shown to undergo osteogenic differentiation through various 
applied techniques and in vitro mediums, such as when: encapsulated in alginate microbeads, when grown on 
fast-resorbable calcium phosphate bone cement, when seeded on specially designed polycaprolactone-collagen- 
hydroxyapatite nanofibrous scaffolds and when seeded into injectable calcium phosphate-alginate hydrogel 
paste [2]. 
3.5. Seeding Density for 3D Biomaterial Cultures 
It was discovered that the seeding density required for optimum differentiation and growth was that of 25 mil-
lion cells/ml or more. It was also noted that switching to an anabolic medium IGF-1 with poly (L-lactic acid) 
from an osteogenic medium containing dexamethasone and vitamin D3 was not favourable [27]. 
3.6. Different Constructs for HUCMSC Differentiation and Bone Formation and in Vitro 
Studies in Mice 
In order to evaluate promotion of osteogenesis and chondrogenesis in different constructs HUCMSCs were 
seeded into poly(L-lactic acid) scaffolds for 3 weeks with either an osteogenic or chondrogenic medium. These 
constructs were then sutured together, in some cases placing a small coat of undifferentiated HUCMSCs sepa-
rating them. The insertion of HUCMSCs between the constructs significantly bettered the merging of the two 
structures, evidenced by histology, although differentiation was [28]. 
In another attempt, microsphere-based cylindrical scaffolds were designed to release BMP-2 from one side 
and TGF-β from the other side, transitioning in release from one side to the other gradually and continuously. 
While there was evidence of localised Safranin-O staining on the TGF-β side of the cylindrical construct, show-
ing localised chondrogenesis in a chondrosteal approach, as well as a deposition of calcium throughout, differ-
entiation was again restricted [29].  
In a particular study, a method was used were a nano-hydroxyapatite-collagen-poly (L-lactic acid) composite, 
an artificial bone scaffold material, was seeded with HUCMSCs followed by subcutaneous implantation into 
mice. Although osteoblasts were detected after 12 weeks, using transmission electron microscopy, unfortunately 
no further investigations were conducted to see if these cells were differentiated HUCMSCs or host mouse cells 
[30]. 
In summary, HUCMSCs share some similar HBMSC osteogenic differentiation pathways: the activation of 
the TAZ and Runx2 gene and the upregulation of osteopontin and osteocalcin, resulting in mineralization. How-
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ever, the in vitro bone differentiating abilities of HUCMSCs, using methods to date, appears inferior to 
HBMSCs. 
3.7. HUCPVCs: Bone Formation, Repair and Regeneration 
Perivascular cells (a subpopulation of umbilical stem cells attained from the Wharton’s jelly and tissue sur-
rounding the umbilical vessels),when exposed to osteogenic medium, were seen to form bone nodules after the 
duration of only 4 - 5 days suggesting better bone differentiation compared to other HUCMSCS [31]. 
Comparing the two mesenchymal stem cells, HUCMSCs and HUCPVCs (human umbilical cord perivascular 
cells), the cell types share similar phenotypes save for CD146+ expression (16.2% in HUCMSCs and a larger 
37.9% of perivascular cells) [32]. Von Kossa staining, although positive with both MSCs, was slightly weaker in 
other HUCMSCs when compared to perivascular cells on exposure to osteogenic medium [2]. 
A recent study was conducted in order to determine the viability of CD146+ HUCPVCs in vivo osteogenesis. 
CD146+ HUCPVCs were introduced to a 3D Gelfoam-alginate complex producing an ectopic bone formation 
model prior to their subcutaneous transplantation into the backs of selected SCID (severe combined immunode-
ficient) mice. After the duration of 6 weeks, X-ray imaging showed that the transplants had undergone ectopic 
mineralisation. While histological staining of transplant sections uncovered osteocytes embedded in newly 
formed matrix, human specific mitochondria immunostaining indicated that the osteocytes nested in the bone 
matrix were of donor (HUCPVC) origin [32].  
In order to assess the functional repair and regenerating abilities of the stem cells, a critical-sized bone defect 
was intentionally produced in the femur of a selected group of SCID, transplanting the 3D CD146+ HUCPVCs- 
Gelfoam-alginate complexes inside the damaged bone site. Newly formed bone was detected in the defect re-
gion on x-ray examination after a duration of 6 weeks after transplantation of CD146+ HUCPVCs transplanta-
tion similar with the previous model involving subcutaneous introduction of the stem cells. Apart from bone, a 
cartilaginous callus was also formed at the site of injury. Using particular techniques of mitochondria staining it 
was determined that not only were the CD146+ HUCPVCs incorporated within the new bone regenerate but 
they were also responsible for the regeneration and repair of the bone defect [33]. 
3.8. Promising Finds in Future Treatment of Osteoporosis 
In a particular study, human umbilical cord blood -derived CD34+ cells were induced to undergo osteogenic 
differentiation and produce bone matrix under the stimulation of osteogenic signals, b-glycerophosphate and 
ascorbic acid. During this study several mice were treated with dexamethasone to bring about a change in bone 
microarchitecture and overall bone loss similar to that brought on by osteoporosis due to disproportionate in-
crease in osteoclasts compared to osteoblasts also inhibiting osteoblastic action. Apart from obliterating bone- 
microarchitecturel, osteoporosis also tends to direct bone marrow differentiation to adipogenesis [34].  
After 28 days following application of the osteoporotic mice with the nanofiber-expanded CD34+ cells, the 
researchers observed a significant increase in osteoblastic activity increasing bone formation and a parallel de-
crease in the number of osteoclasts and adipocytes in osteoporotic sites. Apart from having an osteogenic effect 
on precursor cells, the elevated levels of CXCR4, chemokine receptor, expressed on the nanofiber CD34+ ex-
panded cells were found to be indispensable in directing these CD34+ cells to bone marrow through their bind-
ing to stromal derived factor (SDF)-1 [34].  
Elevated levels of granulocyte macrophage- colony stimulating factor (GM-CSF) secretion further evidenced 
the activity of osteoblastic action while the up-regulation of interleukin -10 (IL-10), a cytokine with anti-osteo- 
clastic activity, evidenced the bone remodeling regulating abilities of the CD34+ in impairing osteoclastogenesis 
and improving bone formation [34]. 
Therefore current findings regarding human cord blood-derived CD34+ cell transplantation have shown the 
ability of these cells to increase trabecular bone formation with an increased trabecular quantity and thickness 
and decreased expression of adipocytes in bone marrow in osteoporosis and thus might prove instrumental in 
future treatment of human osteoporosis. UC derived CD34+ cells have another additional advantage in that ex-
perimental model systems have not shown signs of oncogenic and transformation [34].  
3.9. Clinical Trials 
Few clinical trials have ever been carried out in the use of HUCMSCs for bone regeneration. However, one was 
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recently conducted to explore the benefits of transplanting umbilical cord mesenchymal stem cells and bone 
marrow stem cells together in the possible treatment of avascular necrosis of the femoral head (ANFH). Thirty 
ANFH patients took part in the study (6 females and 24 males: 49 hips). Using the Association Research Circu-
lation Osseous system, 25 of the hips were in phase III while 24 where in phase II [35].  
Bone destruction improved in 89.7% hips (44/49) with a major improvement of bone deposition on the dam-
aged femoral head, refer to Figure 2. Four of the phase III hips actually improved to phase II while the twenty 
four phase II hips, which also seemed to have improved by imaging, stayed in the same phase. Not only did this 
trial prove the efficacy of HUCMSCs and BMSCs in osteogenesis and repair, but the stem cells also lead to the 
restoration and revascularisation of necrotic femoral head as well as gradually improving other symptoms of 
claudication and pain [35]. 
In future human clinical trials should be done to analyse the sole use of umbilical stem cells in repair of dam-
aged bone to better understand and analyse their therapeutic effect [35]. 
4. Neurogenerative and Neuroprotective Abilities of Umbilical Stem Cells 
4.1. Mesenchymal Stem Cells and Umbilical Cells in CNS injury and Neurodegenerative 
Diseases 
Mesenchymal stem cells have proved to be promising in neurogenesis, repair of brain and spinal cord injury re-
pair. Intravenous autologous MSC transplantation conducted in patients suffering from spinal cord injury or 
chronic ischemic stroke, during phase 1 clinical trials, contributed to decreased long-term disability in the pa-
tients undergoing the trial, while patient follow-ups showed and caused no severe adverse consequences related 
to MSC transplantation. What is more is that recent studies and evidence have pointed towards MSC-based 
therapy not only enhancing neurogenesis in brain injury but also increasing the blood supply going towards 
neurones and glial through angiogenesis [7]. 
In recent years HUCMSCs and Wharton jelly MSCs (WJ-MSCs), obtained from umbilical Wharton jelly, 
 
 
Figure 2. New bone regeneration and restoration was observed in patient’s femoral head under imaging 
techniques. Left side of the figure above shows the necrosis at one patient’s left femoral head before under-
going treatment, the upper-inner segment of the femoral head showing signs of capsular transparency (indi-
cated by the white arrow on the left hand side image) in the inner-upper region of femoral head. However, 
after 1 year of treatment the once low-density region was restored with deposition of new bone tissue (as in-
dicated by the white arrow on the right). Adapted from [35].                                                  
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have had various breakthroughs in neural in vitro differentiation into cholinergic [15] and gabaergic [36] neu-
rones as well as had positive outcomes in hippocampal neurone regeneration [37].  
4.2. Evidence on Neuronal Differentiating Abilities 
In a study carried out [38], Wharton’s jelly cells were observed to go through morphological changes also ex-
pressing neural-specific proteins on induction by an adapted method from previous studies [39]. This study was 
one of the first in demonstrating the ability of these easily attainable multipotent stem cells to differentiate into 
neural cells in vitro. In both untreated and treated Wharton’s jelly cells, neurone specific enolase (NSE), a neural 
stem cell marker, was found at approximately equal levels [38] homogenous with results obtained from bone 
marrow stromal cells [39]. Apart from NSE, cultivations of Wharton’s jelly cells were also found to express c- 
kit and TH, the latter being a marker for catecholaminergic neurons [38]. 
During studies carried out by [40] after 3 days of being exposed to a neuronal conditioned medium, 
HUCMSCs started to exhibit and produce neuron-specific proteins such as neurofilament (NF) and NeuN. Past 
the 3rd day various other changes were noted such as the development and elaboration of processes, rescission of 
the cell body and grouping of cells. Within a week the stem cells had started to express functional mRNA ac-
countable for the synthesis of subunits of both glutamate decarboxylase and kainate receptors both essential to 
neuronal function and communication. Within less than two weeks, 87% of HUCMSCs were expressing NF and 
glutamate, the latter invoking an inward current that confirmed the stem cells’ complete differentiation into ma-
ture neurones and achievement of neuronal functionality [40]. 
4.3. Umbilical Stem Cells and Role of Beta1-Integrin in Treatment of Stroke 
HUCMSCs have been found useful in the treatment of stroke in rat models. Transplanted HUCMSCs were ob-
served to differentiate into neuronal and glial cells as well as CXCR4+, doublecortin+, and vascular endothelial 
cells upon migration towards the ischeamic boundary zone, enhancing neuroplasticity in the ischemic brain [41]. 
Increased beta1-integrin expression was found to significally increase expression of neurotrophic factors. On 
the other hand inhibition of beta1-integrin expression not only reduced the ischaemic recovery from neurologi-
cal deficit but inhibited local angiogenesis. Therefore regulation of beta1-integrin expression was also found to 
play a role in neuronal differentiation and plasticity of HUCMSCs particularly in the treatment of the ischemic 
brain [41]. 
4.4. Secretome of Umbilical Stem Cells 
Transplanted MSCs such as Wharton’s Jelly mesenchymal stem cells (WJMSCs) and HUCMSCs not only have 
the capability of directly differentiating into neurons after injection, but also secrete a MSC secretome which has 
an extensive range of immunomodulatory and trophic cytokines that have a substantial potential for the treat-
ment of brain damage via stimulation of endogenous neurogenesis and neuro-protection. Resulting from the lim-
ited control and knowledge of cytokine production succeeding MSC transplantation, harvesting secretome for 
relevant therapeutic outcomes is still proving challenging [7]. The secretome and the MSCs recovered from 
Wharton jelly, have shown particular positive impacts on cell density and metabolic viability of primary hippo-
campal neurons when compared to MSC derived from adipose [37]. However when it comes to neuronal sur-
vival, factors enhancing effects of the WJ-MSC treated media are yet to be discovered. 
4.5. Neurogenerative Abilities of Umbilical Stem Cells Compared to Those of Bone  
Marrow Mesenchymal Stem Cells 
In a study conducted by [7], comparing collected BMSCs and WJ-MSCs, the DAVID (Database for Annotation, 
Visualisation and Integrated Discovery) web-based tool was applied to gene signatures in order to understand 
better the functional consequences of differing gene expression patterns. Using this GO (gene ontology) data-
base system, it was demonstrated that the predominantly overrepresented biological processes in WJ-MSC in-
volved those related to the development of the nervous system through neurogenesis and cell proliferation. Con-
trasting with this outcome, BM-MSCs mainly overrepresented processes pertaining to ossification and the over-
all development of the skeletal system. Identified as neurogenesis transcriptional factors in previous studies, 
PITX1 and SOX11 were observed to be largely expressed in WJ-MSCs and these results were reconfirmed by 
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reverse transcription polymerase chain reaction (RT-PCR). Receptors such as NRP2, FLT1 and CDH2, involved 
in neurogenesis and angiogenesis, were also more numerous in WJ-MSCs when compared to BMSCs [7]. 
4.6. Secretome of BMCs and WJ-MSCs and Their Chemotaxic Abilities on Neuro-2a Cells 
Exploring the secrotome of the MSCs, WJ-MSCs were found to express EGF, MDK, NTF3 and other such neu-
rogenic cytokines in high amounts. The MSCs differed in the up-regulation of specific genes, with BM-MSCs 
namely up-regulating PGF and ANGPT1 expression, and the WJ-MSC up-regulating namely CXCL5, HBEGF, 
CXCL2, FGF9, EGF, NTF3 and MDK. Enzyme-linked immunosorbent assay (ELISA), allowed for the moni-
toring of secreted proteins levels where CXCL5 was produced in significantly higher amounts in the case WJ- 
MSCs and their conditioned medium while the BM-MSC conditioned medium was found to contain higher 
amounts of secreted platelet growth factor (PGF) [7].  
Keeping in mind this difference in up-regulated genes between the two stem cell types as well as the differing 
secretomes, with their own concoction of cytokines and growth factors, the two MSCs were investigated in or-
der to analyse their chemotaxic influence on neural cells as well as their neural enhancing abilities. The BMSCs 
and WJ-MScs were co-cultured separately with mouse Neuro-2a (N2a)cells (cells capable of axonal outgrowth 
and neuron differentiation) in Transwell plates in order to observe the chemotaxic effects on neural cells due to 
the MSCs. Although N2a migration was prompted by both MSCs types, N2a cells were clearly seen to travel 
towards the WJ-MSCs more regularly and quickly [7]. 
4.7. Neuronal Differentiating Abilities of WJ-MSCs and BMSCs Secretomes 
Examining the neuronal differentiation inducing abilities of the MSCs upon N2a, N2a cells were cultured sepa-
rately with the conditioned media from WJ-MSCs and BM-MSCs respectively, collecting the total proteins 
produced after the duration of 4 days [7]. 
Increased NEFL (Neurofilament light polypeptide) and TUBB3 (β-tubulin III) marker expression, originating 
from the WJ-MSC conditioned medium, evidenced the conclusion of better neural differentiation induction of 
the N2a cells. Increased neurite-positive, TUBB3-positive cells were also present upon cultivating the N2a cells 
with WJ-MSC compared to BM-MSC conditioned medium furtherly confirming WJ-MSCs capability in neural 
differentiation induction [7].  
4.8. WJ-MSC Secretome and Its Neuroprotective Effects on Injured by Oxygen-Glucose  
Deprived Primary Cortical Cells 
Comparing the neuroprotective efficacy of BMSCs and WJ-MSCs and their secreted factors in oxygen glucose 
deprevation (OGD), a lab designed ischaemic model of was used to substitute a real life ischaemic insult to the 
central nervous system, WJ-MSCs were found to secrete factors with better neuroprotective qualities than those 
secreted from BM-MSCs. Following OGD, both co-cultures with BM-MSCs and WJ-MSCs, showed a compel-
ling reduction in apoptosis cell death compared to the control, however the WJ-MSC group demonstrated the 
lowest count in cell death and apoptosis rate [7]. 
While the number of branched points, neurite length and overall neuronal proliferation was increased the most 
in the WJ-MSCs, the quantity of astrocytes was decreased in the WJ-MSC group when compared to the BMSCs 
[7]. 
5. Umbilical Stem Cells Use and Treatment in Cerebral Palsy 
5.1. Cerebral Palsy: The Disease 
Cerebral palsy is one most readily identifiable consequence of perinatal brain injury. This condition may occur 
due to chronic or acute injury sustained following birth in the new born period or even before, during the birth-
ing process or during the development of the foetus [6]. Cerebral palsy is characterised by problems in move-
ment and posture as well as disturbances of perception, cognition, communication, sensation and may also 
manifest itself in seizures as well as behavioural changes. The aetiologies causing the perinatal brain insult 
leading to the manifestation of the condition are numerous with the main culprits being: cerebral dysgenesis, 
leukomalacia, intracranial haemorrhage and periventricular intrapartum asphyxia [42]. 
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5.2. Cerebral Palsy and Umbilical Stem Cells: Why Umbilical Stem Cells? 
Currently there are a number of undergoing clinical trials worldwide targeting the use of umbilical stem cells in 
treatment of cerebral palsy. A couple of trials have already had some positive outcomes e.g. [14], but it is still 
going to be a couple of years before the medical community can draw some proper trial-based evidence on the 
use of the umbilical stem cells in cerebral palsy [6].  
Due to the neuroprotective and neurogenerative properties that umbilical stem cells show, mentioned in the 
previous chapter, they have been considered as having promising potential in treatment of cerebral palsy. Um-
bilical cord blood transplantation has been especially promising in treatment of hypoxic-ischemic brain injury 
which is one of the major causes of cerebral palsy [43]. The little trials that have been completed have not been 
made publically available as peer-reviewed reports. Although some trials have now been completed, there have 
little peer-reviewed reports of them published as yet [6]. 
5.3. Case Study Treatment in 5-Year-Old Girl with Cerebral Palsy 
In a case study a cerebral palsy suffering 5-year-old girl, was treated using the umbilical cord of her sibling. The 
patient presented with symptoms of severe dysarthria restraining her speech, ambulation with tumble and other 
symptoms that were associated with retardation of motor function during congenital growth and a disability in 
standing. Upon physical examination and assessment the child’s limb muscular tension appeared normal how-
ever her fine motor skills were lacking in finesse and were overall quite bad. On a psychological level the child 
was quite stressed and apprehensive compared to other children her age [42].  
Although she had no history of epilepsia or chorea and her limbs had a normal muscular tension, she was 
found to lack fine motor skills and measured 48/126 in terms of functional independence. What is so interesting 
and promising about this case is that although neurotrophic drugs and other treatment produced limited positive 
results treating the cerebral palsy with the umbilical cord of her sibling had very positive results [42].  
After processing of the MSCs, 5 - 10 × 106 MSCs in a 20 ml solution were administered per treatment, with 
2ml being delivered by subarachnoid injection via lumbar puncture and 18 mL were delivered intravenously. 
The girl was treated seven times along the course of a year and during this time the patient only had a singular 
episode of mild fever which cleared up in 24 hours and except for rehabilitation training no other medical treat-
ment was administered [42].  
Post treatment (28 months) the patient was seen to improve in various areas, most noticeable of which was the 
major decrease in ambulation with tumble. The patient also developed the ability to stand up without the help of 
anyone. Further improvements included an improved adjustment in comprehension and speech, enhanced im-
munity and overall elevated levels of physical strength. What is more is that the treatment had little to no ad-
verse effects with multiple renal and liver function tests, other blood tests and chest X-rays showing normal pa-
rameters [42].  
This lone case proved that in children, at least, HUCMSCs have the capacity to improve the gross motor dys-
function experienced in cerebral palsy. However investigations into larger scale trials and studies are still going 
to be crucial in determining the possible merit and adverse effects of using these MSCs for cerebral palsy treat-
ment [42].  
5.4. Coupled Treatment of Cerebral Palsy with EPO and Umbilical Cord Blood 
In a recent study the use of umbilical stem cells together with recombinant human erythropoietin (rhEPO) in 
treatment of cerebral palsy in children was assessed in a double-blind placebo- controlled randomized trial in-
volving 105 children. The pUCB group of children were the group that were treated with rhEPO potentiated 
UCB and also received rehabilitation. The second group (EPO group) received rehabilitation and rhEPO with 
placebo UCB. The Control group on the other hand received both placebos, of UCB and rhEPO, only receiving 
the rehabilitation part of the treatment [14].  
The results of the study consistently showed that compared to the control and EPO group, superior therapeutic 
outcomes were observed in the pUCB group. Be it 1-month, 3 months or 6-months post-treatment the children 
improved in both cognitive and motor function. However the motor abilities of the children less than 36 months 
old, according to the GMFM scale, were best improved in the EPO group [14].  
However, apart from this outcome, the rhEPO had little effect, suggesting that the positive results obtained 
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from the pUCB group [14] were mainly down to the UCB, even though rhEPO was expected to have a larger 
therapeutic effect and is described to have neurotrophic abilities [44].  
However, amidst these positive results there were some minor adverse effects, with the pUCB group experi-
encing higher rates of irritability and pneumonia as non-serious adverse effects of the treatment. On intravenous 
administration of the UCB treatment there was an immediate decline in observed blood oxygen saturation. 
However providing the patients with oxygen quickly corrected the defecit. No severe adverse effects were re-
corded and the one death that did occur during the trial was found to be unrelated to treatment itself but rather 
due to the pre-existing severity of the patient’s hypoxic ischaemic encephalopathy [14].  
Due to the fact that EPO was used to boost the neuroprotective efficacy of the UCB, it cannot be taken for 
granted that the outcome of this trial would have been the same without the EPO in the pUCB group. Further 
studies should and are currently being done to study the individual effect of UCB and to highlight the differ-
ences in efficacy between allogenic (coming from matched donor) and autologous (coming from own harvested 
umbilical cord) originating UCB and to further enhance the positive effects of UCB on cerebral palsy. However 
when taking into consideration the severity and frequency of the adverse effects encountered during this study, 
the risks fall short of the overall benefits that lie in considering this new treatment for cerebral palsy [14].  
6. Promising Finds in Umbilical Stem Cell Treatment of Alzheimer’s and Under-
going Clinical Trials 
6.1. Alzheimer’s: the Disease 
Like other neurodegenerative disorders, the umbilical cord (containing stem cells with neurogenerative and 
neuroprotective properties) is being looked into as a possible treatment source for Alzheimer’s disease (AD). 
This neurodegenerative disorder, which has also been described as being progressive and age-related, manifests 
itself in symptoms of serious cognitive decline and memory loss. The pathology of the disease is dominated by 
neuronal loss, deposition of amyloid plaques and neurofibrillary tangles. Having said this, however, increased 
deposition of amyloid β-peptide (Aβ) deposition is the main reason for the loss of neurones in AD [45]. The de-
crease in cognitive function comes from the damage and loss of cholinergic neurones innervating vast areas of 
cerebral cortex in the forebrain [15].  
Therefore in vitro and vivo evidence of WJ-MSCs’, derived from umbilical cord, ability to replace these cho-
linergic neurones through neuronal differentiation as well as reduce the deposition of the destructive amyloid 
protein has given life to the idea of using these umbilical stem cells for the treatment of Alzheimer’s [15] [45]. 
6.2. Differentiation into Cholinergic Neurons 
An in vitro study, conducted recently [15], it was observed that under the influence of fibroblast growth factor 8 
(FGF8) as well as bone morphogenic protein 4 (BMP4), both known for their neural induction abilities [45]-[47], 
Nscm treated WJ-MSCs were found to proliferate towards a cholinergic lineage. Their differentiation was con-
firmed visually through microscopic techniques as well as testing for the production of NF and the upregulation 
of choline acetyltransferase (CHAT) gene for the enzyme required for the production of acetylcholine, the neu-
rotransmitter of cholinergic neurones. These results substantiate promising arguments in WJ-MSCs being for 
AD therapy and a source of cholinergic neurones [15]. 
6.3. Stem Cell Ability to Reduce Levels of Amyloid β-Peptide Deposition in AβPP/PS1 
Transgenic Mice 
In another study conducted on AβPP/PS1 transgenic mouse model, tricyclodecan-9-yl-xanthogenate (D609) in-
duced HUMSCs differentiated into neuron-like cells (HUMSC-NCs), were transplanted into the transgenic AD 
mouse model. The transplantation was found to improve the mice’s cognitive function, reduce substantially the 
Aβ deposition in the mice together with the increase in production of synapsin 1 [45]. 
The cause of these beneficial effects was found to be due to the increase in M2-like microglial activation in 
those transplanted with the HUMSC-NCs, increasing in turn the expression of interleukin-4 (IL-4), a M2-like 
microglia associated anti-inflammatory cytokine. Tumour necrosis factor α (TNF-α) as well as interleukin-1β 
(IL-1 β), both cytokines of a pro-inflammatory nature, typically of M1-like microglial expression were substan-
tially decreased. What is more is that the expression of neprilysin (NEP) and insulin-degrading enzyme (IDE), 
P. Cassar, R. Blundell 
 
 52 
both Aβ degrading entities, were considerably increased in those mice treated with stem cells [45].  
All these results point to the ability of HUMSC-NC transplantation to decrease the deposition of amylin pro-
teins as well as decrease neuroinflamation, both typically seen in Alzheimer’s. Although these results were seen 
in AβPP/PS1 transgenic mice and not in man, this information testifies to the promising cell therapy that um-
bilical stem cells can offer to the Alzheimer’s community with future testing and clinical trials [45].  
6.4. Clinical Trials 
Unfortunately little known clinical trials have been conducted regarding the use of umbilical stem cells in treat-
ment of Alzheimer’s’ disease and the true potential of this stem cell treatment can’t be realised until more time 
and money is invested in human based treatment.  
There is, however, a current ongoing trial that started in 2012 aimed at investigating the tolerability and safety 
of HUCMSCs and the effectiveness of their use in treatment of AD patients [48]. 
7. Conclusions  
In conclusion, it is clear that umbilical stem cells have a large therapeutic potential, having a great advantage 
over other stem cells such as bone marrow and embryological stem cells due to fact that their use comes with lit-
tle ethical issues.  
This review has shed light on a few of the many uses of these stem cells such as their use in cartilage and 
bone formation and regeneration. This review also included evidence-based information on the stem cells’ neu-
rogenerative abilities and the neuroprotective effects of their secretome leading to them being used and studied 
for their therapeutic role in neurodegenerative diseases such as Cerebral palsy and Alzheimer’s. HUMSCs were 
also pointed out to be having more efficient and powerful cartilage and neuronal differentiating abilities when 
compared to bone marrow stem cells, however, still remains mostly outperformed in terms of bone differentiat-
ing abilities. 
The actual use of umbilical stem cells in human clinical trials is still relatively a young concept but is luckily 
growing in popularity with many clinical trials currently underway worldwide assessing the stem cells’ use in 
multitudes of conditions. There have been a few of these trials that have been published already as mentioned in 
this review. However, many more results are yet to be published and trials themselves are yet to be completed. 
So with the promise of ongoing clinical trials, the next couple of years will be more fruitful in revealing in-
formation about the use of these stem cells in humans. However, the preliminary in vitro and in vivo experi-
ments that have been conducted, as well as the human trial results that have been published so far, all point to-
wards umbilical stem cells having great potential in various areas of medicine. 
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Table of Abbreviations 
Abbreviations Meaning 
UC Umbilical Cord 
MSC(s) Mesenchymal Stem Cell(s) 
HUCMSC(s) Human Umbilical Cord Mesenchymal Stem Cell(s) 
BMSC(s) Bone Marrow Derived Mesenchymal Stem Cell(s) 
TGF Tissue Growth Factor 
IGF-1 Insulin Growth Factor-1 
GAG(s) Glycosaminoglycan(s) 
TMJ Temporomandibular Joint 
D3 Dihydroxyvitamin 
ALP Alkaline Phosphatase 
BMP-2 Bone Morphogenic Protein-2 
SCID Severe Combined Immunodeficiency/Deficient 
HUCPVC(s) Human Umbilical Cord Perivacular Cell(s) 
SDF Stromal Derived Factor 
GM-CSF Granulocyte Macrophage-colony Stimulating Factor 
ANFH Avascular necrosis of Femoral Head 
WJ-MSC(s) Wharton Jelly-Mesenchymal Stem Cell(s) 
NSE Neurone Spefic Enolase 
NF Neurofilament 
DAVID Database for Annotation, Visualisation and Integrated Discovery 
GO Gene Ontology 
RT-PCR Reverse Transcriptio-Polymerase Chain Reaction 
ELISA Enzyme Linked Immunosorbent Array 
PGF Platelet Growth Factor 
N2a Neuro-2a 
NEFL Neurofilament Light polypeptide 
TUBB3 β Tubulin III 
OGD Oxygen Glucose Deprivation 
rhEPO Recombinant Human Erythropoietin 
UCB Umbilical cord Blood 
Aβ Amyloid β 
FGF8 Fibroblast Growth Factor 
BMP-4 Bone Morphogenic Protein-4 
CHAT Choline Acetyltransferase 
IL-4 Interleukin-4 
TNFα Tumour Necrosis Factor α 
IL-1β Interleukin-1β 
NEP Neprilysin 
IDE Insulin Degrading Enzyme 
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